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In adult patients with inoperable locally advanced or
metastatic soft-tissue sarcoma, do combination che-
motherapy regimens containing ifosfamide have an
advantage in terms of response rate, time to progres-
sion, or survival, as compared with similar regimens
without ifosfamide when used as first-line therapy?
What are the adverse effects and effects on qual-
ity of life of ifosfamide-containing combination che-
motherapy as compared with similar regimens
without ifosfamide?
Perspectives
The prognosis for patients with inoperable or meta-
static soft-tissue sarcoma (STS) remains grim. Al-
though the surgical resection of pulmonary metastases
may be curative in 15%–30% of patients with iso-
lated slow-growing metastases, most patients receive
chemotherapy for palliative purposes. Ifosfamide has
documented activity in patients who have received
prior treatment with, or who have progressed on,
doxorubicin. A number of studies have suggested a
schedule and a dose–response relationship for
ifosfamide in metastatic STS. Ifosfamide has also been
assessed in combination with other drugs such as
doxorubicin and dacarbazine (DTIC); results of such
studies have led some authors to suggest that
polychemotherapy using “appropriate doses” of
ifosfamide and doxorubicin may represent the “most
effective systemic treatment” in this population.
Given the limited effective therapeutic options avail-
able for patients with metastatic STS, the Sarcoma
Disease Site Group (DSG) felt that a need existed to
more specifically evaluate the potential benefits of
ifosfamide-containing combination chemotherapy in
that setting. The Sarcoma DSG developed an evidence-
based series report through systematic review, evi-
dence synthesis, and input from practitioners across
Ontario.
Outcomes
Outcomes of interest included survival, response rate,
adverse events, and quality of life.
Methodology
A systematic review and meta-analysis served as the
evidentiary base for this clinical practice guideline.
The report was reviewed and approved by the Sar-
coma DSG, which comprises medical oncologists, ra-
diation oncologists, surgeons, methodologists, and
patient representatives. The results of an external re-
view by Ontario practitioners, obtained through a
mailed survey, were incorporated into this report.
Final approval of the evidence-based series report was
obtained from the Report Approval Panel of Cancer
Care Ontario’s Program in Evidence-Based Care
(PEBC).
Results
The current practice guideline reflects a combination
of the draft recommendations (based on the evidence
identified in a systematic review and meta-analysis)
and the external feedback from Ontario practitioners
and the PEBC’s Report Approval Panel.
Cancer Care Ontario’s Program in Evidence-based
Care is sponsored by Cancer Care Ontario and
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Practice Guideline
In patients with metastatic STS, the addition of
ifosfamide to standard first-line doxorubicin-contain-
ing regimens is not recommended over single-agent
doxorubicin.
However, in patients with symptomatic, locally
advanced, or inoperable STS, in whom tumour response
might potentially result in reduced symptomatology
or render a tumour resectable, use of ifosfamide in
combination with doxorubicin is reasonable.
Qualifying Statement
In combination with a doxorubicin-containing regi-
men, the dose of ifosfamide should not exceed
7.5 g/m2, given as either a split bolus or a continuous
infusion.
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1. QUESTIONS
In adult patients with inoperable locally advanced or
metastatic soft-tissue sarcoma (STS), do combination
chemotherapy regimens containing ifosfamide have
an advantage in terms of response rate, time to pro-
gression, or survival, as compared with similar regi-
mens without ifosfamide when used as first-line
therapy?
What are the adverse effects and effects on qual-
ity of life of ifosfamide-containing combination che-
motherapy as compared with similar regimens
without ifosfamide?
2. CHOICE OF TOPIC AND RATIONALE
The prognosis for patients with inoperable or meta-
static STS remains grim. Although surgical resection
of pulmonary metastases may be curative in 15%–
30% of patients with isolated, slow-growing me-
tastases 1,2, most patients receive chemotherapy for
palliative purposes.
Ifosfamide has documented activity in patients
who have received prior treatment with, or who have
progressed on, doxorubicin 3–6.A number of studies
have suggested a schedule and dose–response rela-
tionship for ifosfamide in metastatic STS 6–8. The drug
has also been assessed in combination with other
drugs such as doxorubicin and dacarbazine
(DTIC) 6,9,10. The results of such studies have led some
authors to suggest that polychemotherapy with “ap-
propriate doses” of ifosfamide and doxorubicin may
represent the “most effective systemic treatment” in
this population.
Given the limited effective therapeutic options
available to patients with metastatic STS, the Sarcoma
DSG felt that a need existed to more specifically evalu-
ate the potential benefits of ifosfamide-containing
combination chemotherapy in that setting.
3. METHODS
3.1 Guideline Development
The present practice guideline was developed by the
Sarcoma Disease Site Group (DSG) of Cancer Care
Ontario’s Program in Evidence-based Care (PEBC),
using the methods of the practice guidelines devel-
opment cycle 11. This practice guideline is a conve-
nient and up-to-date source of the best available
evidence on ifosfamide-based combination chemo-
therapy for patients with inoperable locally advanced
or metastatic STS. The body of evidence in this report
is composed primarily of data from mature random-
ized controlled trials (RCTs). That evidence forms the
basis of a clinical practice guideline developed by
the Sarcoma DSG. The systematic review (which is
under consideration for publication elsewhere) and
the companion practice guideline are intended to pro-
mote evidence-based practice in Ontario, Canada. The
evidence was selected and reviewed by one member
of the Sarcoma DSG and by methodologists. Mem-
bers of the Sarcoma DSG disclosed information on
potential conflicts of interest. No conflicts were de-
clared. The PEBC is editorially independent of Cancer
Care Ontario and the Ontario Ministry of Health and
Long-Term Care.
External review is obtained for all practice guide-
line reports through a mailed survey of Ontario prac-
titioners. The survey consists of items that address
the quality of the draft practice guideline report and
recommendations, and that ask whether the recom-
mendations should serve as a practice guideline. Final
approval of the practice guideline report is obtained
from the PEBC’s Report Approval Panel (RAP).
3.2 Literature Search Strategy
The MEDLINE (1966 to July 2005), EMBASE (1980 to
July 2005), and Cochrane Library (2004, Issue 3)
databases were systematically searched for eligible
randomized controlled phase II and III trials, practice
guidelines, systematic reviews, and meta-analyses.
In addition, conference proceedings of the American
Society of Clinical Oncology (1997 to Spring 2005)
were searched for abstracts of relevant trials.
4. LITERATURE SEARCH RESULTS
The literature search identified three randomized
phase III trials 9,10,12 and twenty-three single-arm
phase II trials 6,13–34 that met the inclusion criteria for
this systematic review of the evidence.
All three RCTs 9,10,12 and sixteen of the phase II
trials 6,14–28 used ifosfamide with an anthracyclinePRACTICE GUIDELINE SERIES
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(doxorubicin or epirubicin). The remaining seven
phase II studies 13,29–34 used ifosfamide in combina-
tions that did not include an anthracycline. Two of
the RCTs 10,12 reported that the addition of ifosfamide
to an anthracycline regimen (either doxorubicin, or
doxorubicin and DTIC) significantly improved the re-
sponse rate (34%, p = 0.03, and 32%, p < 0.005, re-
spectively). The RCT by Antman et al. 12 also reported
a significant improvement in overall survival (p =
0.04) for patients who received doxorubicin and DTIC
as compared with patients who received MAID (mesna,
doxorubicin, ifosfamide, and DTIC). The reason for
that finding cannot be discerned from the trial, but
histologic differences in the trial population could
possibly have resulted in subtle imbalances in the
treatment arms.
All three RCTs reported higher rates of adverse
events in the regimens that contained ifosfamide. Two
of the trials reported that grades 3 and 4 adverse
events were much higher in the ifosfamide arm 10,12.
Both trials reported a total of 11 toxic deaths, plus
increased hematologic toxicity [myelosuppression
(80%) and leucopenia (86%)].
Although the DSG identified and referenced a num-
ber of phase II trials that conformed to the inclusion
criteria for the present guideline, the results of those
trials were non-contributory to the final guideline
recommendations. The original Sarcoma DSG report
(found at www.cancercare.on.ca/) includes the com-
plete phase II information.
5. DSG CONSENSUS PROCESS
The draft guideline was circulated to the Sarcoma
DSG for review and discussion. The group agreed that,
although the available evidence indicates that the
addition of ifosfamide may improve tumour response,
that improvement does not translate into a survival
benefit. The evidence also indicates that treatment-
related toxicities are clearly increased with the addi-
tion of ifosfamide to doxorubicin-containing
regimens.
6. PRACTITIONER FEEDBACK
The Sarcoma DSG circulated the draft clinical prac-
tice guideline and systematic review to practitioners
in Ontario for review and feedback.
6.1 Methods
Feedback was obtained through a mailed survey of
74 Ontario practitioners, including medical oncolo-
gists, radiation oncologists, and surgeons. The sur-
vey consisted of items evaluating the methods, results,
and interpretive summary used to inform the draft
recommendations and asking whether the draft rec-
ommendations should be approved as a practice
guideline. Written comments were invited. The sur-
vey was mailed February 22, 2006. Follow-up re-
minders were sent at 2 weeks (post card) and 4 weeks
(complete package mailed again). The Sarcoma DSG
reviewed the results of the survey.
6.2 Results
From among 74 surveys mailed, 29 responses were
received (39% response rate). Responses included
returned completed surveys, plus telephone, fax, and
e-mail responses.
Of the practitioners who responded, 9 indicated
that the report was relevant to their clinical practice,
and they completed the survey. One practitioner was
unsure whether the guideline was relevant to personal
practice, and so that practitioner’s comments were
not included in the results. Another indicated that the
topic was relevant, but did not complete the ques-
tionnaire because of concerns that direct contact with
patients was not part of current personal work. Of
the respondents surveyed, most agreed (87.5%) that
a need for a guideline on this topic existed, that the
recommendations in the report were clear, and that
the draft report should be approved as a practice
guideline. All practitioners surveyed agreed with the
recommendations as stated in the draft.
6.3 Summary of Written Comments and
Modifications/Actions
Of the 9 survey respondents, 1 provided suggestions
for future document development and content. Those
suggestions were noted at the PEBC. One practitioner
noted an error regarding the presentation of study
results in the Discussion section. The error was cor-
rected in the report.
7. REVIEW AND APPROVAL BY THE PEBC
REPORT APPROVAL PANEL
The final evidence-based series report was also re-
viewed and approved by the PEBC RAP, which consists
of two members, including an oncologist with ex-
pertise in clinical and methodologic issues. Key is-
sues raised by the RAP were that the inclusion of the
word “routine” in the recommendation created am-
biguity in light of the compelling evidence demon-
strating lack of benefit, and that a rationale for using
response as an important and policy-determining
outcome was required, as was a rationale for includ-
ing phase II studies, given the availability of three
RCTs.
In response, the DSG removed the word “routine”;
noted that, given the limited treatment options, re-
sponse is an important outcome in this patient popu-
lation; and noted that the inclusion of phase II studies
reflects an approach previously used (at the time the
report was initially started) of including RCTs and
phase II studies alike.VERMA et al.
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8. PRACTICE GUIDELINE
The current practice guideline integrates the draft
practice guideline with feedback gathered by exter-
nal review. This report has been approved by the
Sarcoma DSG and the PEBC RAP.
8.1 Recommendation
In patients with metastatic STS, the addition of
ifosfamide to standard first-line doxorubicin-contain-
ing regimens is not recommended over single-agent
doxorubicin. However, in patients with symptomatic
locally advanced or inoperable STS, in whom tumour
response might potentially result in reduced symp-
tomatology or render a tumour resectable, it is rea-
sonable to use ifosfamide in combination with
doxorubicin.
8.2 Qualifying Statements
In combination with a doxorubicin-containing regi-
men, the dose of ifosfamide should not exceed
7.5 g/m2, given as either a split bolus or a continuous
infusion.
9. PRACTICE GUIDELINE DATE
Completed April 2006. Practice guidelines developed
by the PEBC are reviewed and updated regularly. Please
visit the Cancer Care Ontario Web site
(www.cancercare.on.ca/) for the full evidence-based
series report and subsequent updates.
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